Par Pharmaceutical vs. Long Grove: Vasopressin Patent Suit Dismissed
A pharmaceutical patent infringement suit filed by Par Pharmaceutical, Inc., Par Sterile Products, LLC, and Endo Par Innovation Company, LLC against Long Grove Pharmaceuticals, LLC concluded with a Stipulation of Dismissal Without Prejudice on July 25, 2024 — just 230 days after it was filed in the U.S. District Court for the District of Delaware. Presided over by Chief Judge Gregory B. Williams, the case centered on two issued U.S. patents covering vasopressin injection formulations and the defendant’s competing generic product.
For patent attorneys, IP professionals, and pharmaceutical R&D teams, this case offers a window into the litigation dynamics surrounding vasopressin drug patent protection — a commercially sensitive area given the high-stakes market for critical care vasopressors. The dismissal without prejudice leaves open the possibility of future action, making this case a live reference point for competitive intelligence and patent risk management in the parenteral drug space.
Case No.: 1:23-cv-01412 | Court: D. Del. | Closed: July 25, 2024
Was möchten Sie als Nächstes tun?
Wählen Sie Ihren Weg entsprechend Ihren aktuellen Bedürfnissen:
📋 Fallzusammenfassung
| Fallbezeichnung | Par Pharmaceutical, Inc. v. Long Grove Pharmaceuticals, LLC |
| Fallnummer | 1:23-cv-01412 (D. Del.) |
| Gericht | US-Bezirksgericht für den Bezirk Delaware |
| Dauer | Dec 2023 – Jul 2024 7 months |
| Ergebnis | Ohne Präjudiz abgewiesen |
| Streitige Patente | |
| Beschuldigte Produkte | Vasopressin Injection formulations (0.2 Unit/mL, 0.4 Unit/mL, 1.0 Unit/mL) |
Fallübersicht
Die Parteien
⚖️ Kläger
Affiliated entities within the Endo International corporate family, responsible for branded pharmaceutical products including VASOSTRICT® (vasopressin injection).
🛡️ Beklagter
Pharmaceutical company pursuing regulatory approval for generic vasopressin injection products under NDA No. 204485.
Die streitigen Patente
Two U.S. patents were asserted in this action, both covering vasopressin injection formulations and methods of treatment:
- • U.S. Patent No. 9,993,520 B2 (Application No. 15/688,334)
- • U.S. Patent No. 11,207,372 B2 (Application No. 16/291,796)
Both patents relate to the pharmaceutical composition and use of vasopressin, a critical care hormone used to raise blood pressure in patients with vasodilatory shock.
Entwicklung eines Generikums?
Check if your formulation might infringe these or related patents before launch.
Das Urteil und die rechtliche Analyse
Ergebnis
The case was terminated via a Stipulation of Dismissal Without Prejudice — meaning neither party obtained a judicial determination on the merits of infringement or patent validity. No damages were awarded, no injunctive relief was granted or denied by the court, and no claim construction order was issued based on available case data.
A dismissal without prejudice is legally significant: it does not bar the plaintiffs from re-filing the same claims against Long Grove Pharmaceuticals in the future, provided applicable statutes of limitations and procedural requirements are satisfied.
Wichtige rechtliche Fragen
The infringement action was predicated on Long Grove’s alleged infringement of U.S. Patent Nos. 9,993,520 and 11,207,372 through its vasopressin injection products. Given the NDA-referencing framework underlying the dispute, this case bears hallmarks of Hatch-Waxman Act litigation, where branded pharmaceutical manufacturers assert patents against generic applicants seeking approval based on existing NDAs.
Hatch-Waxman litigation frequently resolves through negotiated settlement or licensing arrangements before reaching trial, which is consistent with this case’s rapid dismissal timeline. The **230-day duration** is notably shorter than the typical pharmaceutical patent trial cycle, reinforcing the inference that settlement or licensing discussions drove the resolution — though the specific terms of any underlying agreement were not disclosed in the case record.
The assertion of both U.S. 9,993,520 and the later-issuing U.S. 11,207,372 demonstrates Par’s use of a continuation patent portfolio strategy to extend protection across the vasopressin formulation space, a common and effective tactic in pharmaceutical IP prosecution.
Freedom to Operate (FTO) Analysis for Vasopressin Formulations
Dieser Fall verdeutlicht die kritischen IP-Risiken bei der Entwicklung von Generika. Wählen Sie Ihren nächsten Schritt:
📋 Die Auswirkungen dieses Falls verstehen
Informieren Sie sich über die spezifischen Risiken und Auswirkungen dieses Rechtsstreits.
- Alle zugehörigen Patente in diesem Technologiebereich anzeigen
- See which companies are most active in vasopressin patents
- Verstehen Sie die Muster der Anspruchskonstruktion für pharmazeutische Formulierungen.
🔍 Das Risiko meines Produkts überprüfen
Run a comprehensive FTO analysis for your own generic pharmaceutical product.
- Geben Sie Ihre Produktbeschreibung oder technischen Merkmale ein.
- KI identifiziert potenziell blockierende Patente
- Erhalten Sie einen umsetzbaren Risikobewertungsbericht
Hochrisikogebiet
Vasopressin injection formulations
2 geltend gemachte Patente
In vasopressin formulation space
FTO-Freigabe kritisch
Für die Entwicklung von Generika
✅ Wichtigste Erkenntnisse
Dismissal without prejudice in Hatch-Waxman cases rarely signals a plaintiff’s defeat — often reflecting a negotiated settlement.
Verwandte Rechtsprechung suchen →Continuation patent portfolios (e.g., ‘520 → ‘372) remain powerful enforcement and licensing tools in pharmaceutical litigation.
Präzedenzfälle erkunden →Delaware District Court continues to be the preferred venue for complex pharmaceutical patent disputes due to its experienced judiciary.
View D. Del. litigation data →Häufig gestellte Fragen
Two U.S. patents were asserted: U.S. Patent No. 9,993,520 B2 (App. No. 15/688,334) and U.S. Patent No. 11,207,372 B2 (App. No. 16/291,796), both covering vasopressin injection formulations.
The case was terminated via a Stipulation of Dismissal Without Prejudice, indicating a mutual resolution between the parties without a court ruling on infringement or validity. Specific settlement terms were not disclosed.
The without-prejudice dismissal preserves plaintiffs’ litigation rights, meaning these patents may be asserted again against Long Grove or other generic competitors. Companies in the vasopressin space should monitor this patent family closely.
Sind Sie bereit, Ihre Strategie für pharmazeutische Patente zu stärken?
Schließen Sie sich den über 18.000 Fachleuten aus dem Bereich des geistigen Eigentums an, die PatSnap Eureka nutzen, um mit KI-gestützter Präzision Recherchen zum Stand der Technik durchzuführen, Patentanmeldungen zu erstellen und Wettbewerbslandschaften zu analysieren.
Referenzen
- United States Patent and Trademark Office — Patent 9,993,520 B2
- United States Patent and Trademark Office — Patent 11,207,372 B2
- PACER Case Locator – D. Del. 1:23-cv-01412
- Delaware District Court IP Docket
- PatSnap — IP Intelligence for Pharmaceuticals
Dieser Artikel dient ausschließlich zu Informationszwecken und stellt keine Rechtsberatung dar. Alle Angaben zu den Fällen stammen aus öffentlich zugänglichen Gerichtsakten. Informationen zu den Funktionen der Plattform finden Sie auf PatSnap.